【24h】

Quinacrine sterilization for human immunodeficiency virus-positive women.

机译:奎纳克林对人免疫缺陷病毒阳性妇女的绝育。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate the safety of nonsurgical quinacrine sterilization for HIV-positive (HIV+) women. DESIGN: An open trial of quinacrine sterilization was carried out in women infected with HIV and women who were HIV negative (HIV-). Comparison of the results with the two groups provided an assessment of the safety and effectiveness of quinacrine sterilization for HIV+ women. SETTING: University Medical School outpatient services. PATIENT(S): A total of 258 women who desired sterilization were offered quinacrine sterilization as a means of limiting family size. Sixty-four were HIV+, and 194 were HIV-. Women who were HIV+ had CD4 counts >200 and were otherwise healthy. INTERVENTION(S): A modified Copper T intrauterine device inserter was used to place 252 mg of quinacrine, divided into seven pellets (36 mg each) into the uterine cavity. Three insertions of this formulation were performed, 1 month apart. Viral load and CD8 and CD4 lymphocytes were measured both before and after quinacrine sterilization and at follow-up visits. Pregnancies and adverse events were recorded carefully. A decrement life table was made to statistically analyze results. RESULT(S) AND MAIN OUTCOME MEASURE(S): No serious adverse event occurred in any patient in this study. Adverse effects related to quinacrine sterilization were abdominal cramping, vulvar itching, nausea, and vaginal bleeding. Vaginal bleeding was the only short-term side effect noted to occur more frequently in HIV-infected women after quinacrine sterilization. Among HIV+ women, 35.9% had complaints of increased bleeding, whereas only 8.2% of those who were HIV- had such complaints, which probably were insertion related. Viral load and the CD4+ and CD8+ lymphocyte measures displayed no statistically significant difference after quinacrine sterilization. CONCLUSION(S): Quinacrine sterilization is a safe method for the sterilization of HIV-infected women and has no short-term effect on the pathology of the disease.
机译:目的:评估奎纳克林非手术绝育对HIV阳性(HIV +)妇女的安全性。设计:对感染了艾滋病毒的妇女和艾滋病毒阴性(HIV-)的妇女进行了奎纳克林灭菌的公开试验。将结果与两组进行比较,可以评估奎纳克林杀菌对HIV +妇女的安全性和有效性。地点:大学医学院的门诊服务。患者:共有258名需要绝育的妇女接受了奎纳克林绝育术,以限制家庭规模。 HIV +占64,而HIV-则为194。感染HIV +的女性的CD4计数> 200,否则健康。干预:使用改良的铜T宫内节育器插入器将252 mg奎纳克林放入子宫腔中,分成七个小丸(每个36 mg)。间隔1个月进行了3次该制剂的插入。在奎纳克林灭菌之前和之后以及随访时均测量了病毒载量以及CD8和CD4淋巴细胞。认真记录怀孕和不良事件。制作了减量寿命表以对结果进行统计分析。结果和主要观察指标:在本研究中,任何患者均未发生严重的不良事件。与奎纳克林灭菌有关的不良反应是腹部绞痛,外阴瘙痒,恶心和阴道出血。奎纳克林灭菌后,阴道出血是唯一在HIV感染妇女中更频繁发生的短期副作用。在HIV +妇女中,有35.9%的人抱怨出血增加,而在HIV-中只有8.2%的人抱怨这种情况,可能与插入有关。奎纳克林灭菌后,病毒载量以及CD4 +和CD8 +淋巴细胞的测定无统计学意义的差异。结论:奎纳克林灭菌是对HIV感染妇女进行灭菌的一种安全方法,对疾病的病理没有短期影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号